Is NCT02113813 results overdue?

Yes — results are overdue. Primary completion was 2017-07-28; the FDAAA-801 reporting deadline (2018-07-28) passed 2885 days ago and no results are posted on ClinicalTrials.gov.

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

NCT ID	NCT02113813 ↗
Sponsor	Astellas Pharma Global Development, Inc. (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-07-28 (ACTUAL)
Reporting deadline	2018-07-28 (completion + 365d)
Days overdue	2885
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `2ae91ee146c2c65f…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02113813. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.